

Freedom of Information Request: Our Reference CTMUHB_325_22

You asked:

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- Abemaciclib (Verzenios) + aromatase inhibitor *
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
- Alpelisib (Piqray) + Fulvestrant (Faslodex)
- Atezolizumab (Tecentriq)**
- Bevacizumab (Avastin)
- Eribulin (Halaven)
- Everolimus (Afinitor) + Exemestane
- Fulvestrant (Faslodex) as a single agent
- Gemcitabine + paclitaxel
- Herceptin (Trastuzumab) + paclitaxel
- Herceptin (Trastuzumab) as a single agent
- Lapatinib (Tyverb)
- Neratinib (Nerlynx)
- Olaparib (Lynparza)
- Palbociclib (Ibrance) + aromatase inhibitor*
- Palbociclib (Ibrance) + Fulvestrant (Faslodex)
- Pertuzumab (Perjeta) + trastuzumab + docetaxel
- Ribociclib (Kisqali) + aromatase inhibitor*
- Ribociclib (Kisqali) + Fulvestrant (Faslodex)
- Talazoparib (Talzenna)
- Trastuzumab emtansine (Kadcyla)
- Other active systemic anti-cancer therapy **

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

Our response:

We can confirm that Cwm Taf University Health Board does not hold the information you require. Cwm Taf residents receive breast cancer treatment from the Velindre Cancer Centre, Velindre NHS Trust. Therefore, you will need to redirect your request to Velindre, who provide these services to Cwm Taf residents.

Contact details for Velindre are shown in the following link:

<http://www.velindre-tr.wales.nhs.uk/freedom-of-information-contacts>